정신분열병과 면역학적 이상

키워드

참고문헌 (207)

1. Bruce LC., "Clinical and experimental observations on catatonia", J Ment Sci, 49, pp.614~628 (1903)
2. Lehmann-Facius H., "Serologisch-analytische Versuche mit Liquores und Seren von Schizophrenen", Allg Z Psychiatrie, 110, pp.232~243 (1939)
3. Heath RG., "Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques", Arch Gen Psychiatry, 16(1), pp.1~9 (1967)
4. Torrey EF., "The viral hypothesis of schizophrenia", Schizophr Bull, 2(1), pp.136~146 (1976)
5. Jacobs K., "Schizophrenia and the immune system", pp.46~48 (2006), Harvard Sci Rev
6. Korschenhausen DA., "Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes", Schizophr Res, 19(2), pp.103~109 (1996)
7. Jones AL., "Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?", Immunol Cell Biol, 83(1), pp.9~17 (2005)
8. Brett FM., "Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes", J Neuropathol Exp Neurol, 54(6), pp.766~775 (1995)
9. Frei K., "On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases", Eur J Immunol, 19(4), pp.689~694 (1989)
10. Kipnis J., "cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions", Proc Natl Acad Sci U S A, 101(21), pp.8180~8185 (2004)
11. Jun TY., "Polymorphism of CTLA-4 gene at position 49 of exon 1 may be associated with schizophrenia in the Korean population", Psychiatry Res, 110(1), pp.19~25 (2002)
12. Adams DD., "An informative case of Graves' disease with implications for schizophrenia", J Clin Lab Immunol, 53, pp.13~25 (2004)
13. Knight JG., "Autoantibodies against brain septal region antigens specific to unmedicated schizophrenia?", Biol Psychiatry, 28(6), pp.467~474 (1990)
14. Knight JG., "Rationale for a trial of immunosuppressive therapy in acute schizophrenia", Mol Psychiatry, 12(5), pp.424~431 (2007)
15. Stevens B., "The classical complement cascade mediates CNS synapse elimination", Cell, 131(6), pp.1164~1178 (2007)
16. Fourgeaud L., "Synapse remodeling, compliments of the complement system", Cell, 131(6), pp.1034~1036 (2007)
17. Ganguli R., "Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms", Arch Gen Psychiatry, 52(8), pp.668~672 (1995)
18. Cazzullo CL., "Cytokines production in chronic schizophrenia patients with or without paranoid behaviour", Prog Neuropsychopharmacol Biol Psychiatry, 22(6), pp.947~957 (1998)
19. Ganguli R., "Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness", Psychiatry Res, 51(1), pp.1~10 (1994)
20. Gaughran F., "Increased soluble interleukin 2 receptor levels in schizophrenia", Schizophr Res, 29(3), pp.263~267 (1998)
21. Kim YK., "Decreased interleukin-2 production in Korean schizophrenic patients", Biol Psychiatry, 43(9), pp.701~704 (1998)
22. Muller N., "Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia", Am J Psychiatry, 156(4), pp.634~636 (1999)
23. Theodoropoulou S., "Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients", Schizophr Res, 47(1), pp.13~25 (2001)
24. Villemain F., "Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production", Am J Psychiatry, 146(5), pp.609~616 (1989)
25. Zhang XY., "Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia", J Clin Psychiatry, 65(7), pp.940~947 (2004)
26. O'Donnell MC., "Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder", Psychiatry Res, 65(3), pp.171~178 (1996)
27. McAllister CG., "Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status", Am J Psychiatry, 152(9), pp.1291~1297 (1995)
28. Barak V., "Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients", J Basic Clin Physiol Pharmacol, 6(1), pp.61~69 (1995)
29. Rapaport MH., "Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins", Eur Arch Psychiatry Clin Neurosci, 243(1), pp.7~10 (1993)
30. Rapaport MH., "Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia", Acta Psychiatr Scand, 90(5), pp.311~315 (1994)
31. Mittleman BB., "Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease", J Immunol, 159(6), pp.2994~2999 (1997)
32. Akiyama K., "Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration", Schizophr Res, 37(1), pp.97~106 (1999)
33. Lin A., "The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6", Schizophr Res, 32(1), pp.9~15 (1998)
34. Maes M., "Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine", Acta Psychiatr Scand, 89(5), pp.346~351 (1994)
35. Zhang XY., "Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology", Schizophr Res, 57(2), pp.247~258 (2002)
36. Maes M., "Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers", J Psychiatr Res, 29(2), pp.141~152 (1995)
37. Kim YK., "Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics", Schizophr Res, 44(3), pp.165~175 (2000)
38. Naudin J., "Elevated circulating levels of IL-6 in schizophrenia", Schizophr Res, 20(3), pp.269~273 (1996)
39. Kaminska T., "Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics", Med Sci Monit, 9(7), pp.71~75 (2003)
40. Maes M., "In vivo immunomodulatory effects of clozapine in schizophrenia", Schizophr Res, 26(2), pp.221~225 (1997)
41. Muller N., "The role of immune function in schizophrenia: an overview", Eur Arch Psychiatry Clin Neurosci, 249(4), pp.62~68 (1999)
42. Maes M., "Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor", Schizophr Res, 54(3), pp.281~291 (2002)
43. Kim SJ, "Changes of Interleukin-12 and Transforming Growth Factor Beta 1 before and after Antipsychotic Treatments in Schizophrenic Patients", Korean J Biol Psychiatry, 12, pp.143~150 (2005)
44. Kim YK., "The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs", Mol Psychiatry, 7(10), pp.1107~1114 (2002)
45. Kowalski J., "Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia", Schizophr Res, 50(3), pp.169~175 (2001)
46. Erbagci AB., "Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment", Mediators Inflamm, 10(3), pp.109~115 (2001)
47. Cazzullo CL., "Cytokine profiles in drug-naive schizophrenic patients", Schizophr Res, 47(2), pp.293~298 (2001)
48. Kim YK., "Th1, Th2 and Th3 cytokine alteration in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 28(7), pp.1129~1134 (2004)
49. Preble OT., "Serum interferon in patients with psychosis", Am J Psychiatry, 142(10), pp.1184~1186 (1985)
50. Rothermundt M., "Production of cytokines in acute schizophrenic psychosis", Biol Psychiatry, 40(12), pp.1294~1297 (1996)
51. Strous RD., "Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited", J Autoimmun, 27(2), pp.71~80 (2006)
52. Zalcman S., "Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6", Brain Res, 643(1), pp.40~49 (1994)
53. Denicoff KD., "The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells", Ann Intern Med, 107(3), pp.293~300 (1987)
54. Bessler H., "Cytokine production in drug-free and neuroleptic-treated schizophrenic patients", Biol Psychiatry, 38(5), pp.297~302 (1995)
55. Hornberg M., "Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia", Schizophr Res, 15(3), pp.237~242 (1995)
56. Rothermundt M., "Immunological dysfunction in schizophrenia: a systematic approach", Neuropsychobiology, 37(4), pp.186~193 (1998)
57. Kim YK., "The effect of haloperidol on serum levels of Interleukins in schizophrenic patients", J Korean Neuropsychiatric Assoc, 36(1), pp.80~84 (1997)
58. Kim DJ., "Effect of risperidone on serum cytokines", Int J Neurosci, 111(1), pp.11~19 (2001)
59. Na KS., "Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia", Neuropsychobiology, 56(2), pp.55~63 (2007)
60. Rapaport MH., "Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients", Biol Psychiatry, 35(10), pp.767~771 (1994)
61. Maes M., "Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression", Eur Arch Psychiatry Clin Neurosci, 244(6), pp.325~329 (1995)
62. Frommberger UH., "Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission", Eur Arch Psychiatry Clin Neurosci, 247(4), pp.228~233 (1997)
63. Dunn AJ., "The role of interleukin-1 and tumor necrosis factor alpha in the neurochemical and neuroendocrine responses to endotoxin", Brain Res Bull, 29(6), pp.807~812 (1992)
64. Muraguchi A., "The essential role of B cell stimulatory factor 2 (BSF-2", IL-6) for the terminal differentiation of B cells, 1988, pp.167(2), 332~344
65. Spangelo BL., "Interleukin-6 stimulates anterior pituitary hormone release in vitro", Endocrinology, 125(1), pp.575~577 (1989)
66. Hama T., "Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures", Neuroscience, 40(2), pp.445~452 (1991)
67. Inglot AD., "Interferon responses in schizophrenia and major depressive disorders", Biol Psychiatry, 35(7), pp.464~473 (1994)
68. Arolt V., "Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment", Mol Psychiatry, 5(2), pp.150~158 (2000)
69. Wilke I., "Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients", Eur Arch Psychiatry Clin Neurosci, 246(5), pp.279~284 (1996)
70. Naudin J., "A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?", Schizophr Res, 26(2), pp.227~233 (1997)
71. Schwarz MJ., "Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients", Biol Psychiatry, 47(1), pp.29~33 (2000)
72. Schwarz MJ., "Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease", Am J Psychiatry, 156(7), pp.1103~1104 (1999)
73. Muller N., "Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology", Schizophr Res, 14(3), pp.223~228 (1995)
74. Gallien M., "Antinuclear antibodies and lupus cells in 600 hospitalized, phenothiazine treated patients", Ann Med Psychol Med, 1, pp.237~248 (1977)
75. Zarrabi MH., "Immunologic and coagulation disorders in chlorpromazine treated patients", Ann Intern Med, 91, pp.194~199 (1979)
76. Riedel M., "Decreased T cellular immune response in schizophrenic patients", J Psychiatr Res, 41, pp.3~7 (2007)
77. Yolken RH., "Infectious agent and gene-environmental interactions in the etiopathogenesis of schizophrenia", Clin Neurosci Res, 6, pp.97~109 (2006)
78. Fukuda R., "No changes in paired viral antibody titers during the course of acute schizophrenia", Neuropsychobiology, 40(2), pp.57~62 (1999)
79. Bechter K., "Expanded nuclear magnetic resonance studies in Borna disease virus seropositive psychiatric patients and control probands", Nervenarzt, 65(3), pp.169~174 (1994)
80. Chen CH., "High seroprevalence of Borna virus infection in schizophrenic patients, family members and mental health workers in Taiwan", Mol Psychiatry, 4(1), pp.33~38 (1999)
81. Iwahashi K., "Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan", Acta Psychiatr Scand, 96(6), pp.412~415 (1997)
82. Waltrip RW., "Borna disease virus antibodies and the deficit syndrome of schizophrenia", Schizophr Res, 23(3), pp.253~257 (1997)
83. Yamaguchi K., "Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay", Clin Diagn Lab Immunol, 6(5), pp.696~700 (1999)
84. Richt JA., "Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders", J Neurovirol, 3(2), pp.174~178 (1997)
85. Rothermundt M., "Review of immunological and immunopathological findings in schizophrenia", Brain Behav Immun, 15(4), pp.319~339 (2001)
86. Ahokas A., "Altered white cell count, protein concentration and oligoclonal IgG bands in the cerebrospinal fluid of many patients with acute psychiatric disorders", Neuropsychobiology, 14(1), pp.1~4 (1985)
87. Kirch DG., "Abnormal cerebrospinal fluid protein indices in schizophrenia", Biol Psychiatry, 20(10), pp.1039~1046 (1985)
88. Schwarz MJ., "Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia", Neurosci Lett, 253(3), pp.201~203 (1998)
89. Pae CU., "Interleukin-10 Gene Polymorphism in Patients with Schizophrenia", J Korean Neuropsychiatr Assoc, 41, pp.972~979 (2002)
90. Nawa H., "Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines", Neurosci Res, 56(1), pp.2~13 (2006)
91. Nyffeler M., "Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia", Neuroscience, 143(1), pp.51~62 (2006)
92. Burch PRJ., "Schizophrenia: some new etiological considerations", Br J Psychiatry, 110, pp.818~824 (1964)
93. Knight J., "Can autoimmune mechanisms account for the genetic predisposition to schizophrenia?", Br J Psychiatry, 160, pp.533~540 (1992)
94. Gilvarry CM., "Family history of autoimmune diseases in psychosis", Schizophr Res, 19(1), pp.33~40 (1996)
95. Gorwood P., "Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level", Schizophr Res, 66(1), pp.21~29 (2004)
96. Ganguli R., "Autoimmunity in schizophrenia: a review of recent findings", Ann Med, 25(5), pp.489~496 (1993)
97. Kroemer G., "Cytokines and autoimmune disease", Clin Immunol Immunopathol, 61(3), pp.275~295 (1991)
98. Ruschen S., "Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls", Clin Exp Immunol, 89(1), pp.32~37 (1992)
99. Rose NR., "Defining criteria for autoimmune diseases (Witebsky's postulates revisited)", Immunol Today, 14(9), pp.426~430 (1993)
100. Wright P., "Autoimmune diseases in the pedigrees of schizophrenic and control subjects", Schizophr Res, 5(3), pp.261~267 (1996)
101. Gold MS., "Perphenazine-induced systemic lupus erythematosus-like syndrome", J Nerv Ment Dis, 166(6), pp.442~445 (1997)
102. Goldman LS, "Lupus-like illness associated with chlorpromazine", Am J Psychiatry, 137(12), pp.1613~1614 (1980)
103. Wickert WA., "Acute severe adverse clozapine reaction resembling systemic lupus erythematosus", Postgrad Med J, 70(830), pp.940~941 (1994)
104. Nikkila HV., "Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes", Am J Psychiatry, 156(11), pp.1725~1729 (1999)
105. Nikkila HV., "Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia", Schizophr Res, 49(1), pp.99~105 (2001)
106. Heath R., "Schizophrenia as an immunologic disorder: 2. Effects of serum protein factions on brain function", Arch Gen Psychiatry, 16, pp.10~23 (1967)
107. Grosskopf A., "Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes", Schizophr Res, 30(2), pp.187~189 (1998)
108. Herbon N., "High-resolution SNP scan of chromosome 6p21 in pooled samples from patients with complex diseases", Genomics, 81(5), pp.510~518 (2003)
109. Sasaki T., "Schizophrenia and the HLA-DRB1 gene in the Japanese population", Am J Psychiatry, 156(5), pp.771~773 (1999)
110. Wright P., "A transmission", disequilibrium study of the DRB1*04 gene locus on chromosome 6p21.3 with schizophrenia, 1998, pp.32(2), 75~80
111. Wright P., "Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia", Am J Psychiatry, 153(12), pp.1530~1533 (1996)
112. Levine J., "Side effect profile of azathioprine in the treatment of chronic schizophrenic patients", Neuropsychobiology, 36(4), pp.172~176 (1997)
113. DeGiorgio LA., "A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus", Nat Med, 7(11), pp.1189~1193 (2001)
114. Bergen JR., "Immunologic studies in schizophrenic and control subjects", Biol Psychiatry, 15(3), pp.369~379 (1980)
115. Vilkov GA., "Ultrastructural and biochemical evidence of brain damage by the serum IgG fraction of the blood of schizophrenics", Zh Nevropatol Psikhiatr Im S S Korsakova, 84(5), pp.767~770 (1984)
116. Borda T., "Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera", Glia, 45(2), pp.144~154 (2004)
117. DeLisi LE., "Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus", Biol Psychiatry, 20(1), pp.110~115 (1985)
118. Henneberg AE., "Increased prevalence of antibrain antibodies in the sera from schizophrenic patients", Schizophr Res, 14(1), pp.15~22 (1994)
119. Kuznetoza NI., "Detection of antibrain antibodies in the sera of patients with neuropsychiatric disorders", Zh Nevropatol Psychiatry, 61, pp.869~873 (1961)
120. Logan DG., "Schizophrenia, an immunologic disorder?", JAWA, 212, pp.1703~1704 (1985)
121. Pandey RS., "Autoimmune model of schizophrenia with special reference to antibrain antibodies", Biol Psychiatry, 16(12), pp.1123~1136 (1981)
122. Teplizki HA., "Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle", Immunol Res, 11(1), pp.66~73 (1992)
123. Sundin U., "Antibody reactivity to brain membrane proteins in serum from schizophrenic patients", Brain Behav Immun, 3(4), pp.345~358 (1989)
124. Whittingham S., "Absence of brain antibodies in patients with schizophrenia", Br Med J, 1(5588), pp.347~348 (1968)
125. Kelly RH., "Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia", Biol Psychiatry, 22(12), pp.1488~1491 (1987)
126. Plioplys AV., "Anti-CNS antibodies in neurological and psychiatric disorders", J Neurol Neurosurg Psychiatry, 50(11), pp.1514~1521 (1987)
127. Schott K., "Antibrain antibodies in mental disorder: no evidence for antibodies against synaptic membranes", J Neural Transm, 105(4), pp.517~524 (1998)
128. Heath RG., "Antiseptal brain antibody in IgG of schizophrenic patients", Biol Psychiatry, 25(6), pp.725~733 (1989)
129. Pelonero AL., "Autoantibodies to brain lipids in schizophrenia", Am J Psychiatry, 147(5), pp.661~662 (1990)
130. Shima S., "Anticerebral antibodies in functional psychoses", Biol Psychiatry, 29(4), pp.322~328 (1991)
131. Stevens A., "Ganglioside antibodies in schizophrenia and major depression", Biol Psychiatry, 32(8), pp.728~730
132. Yang ZW., "An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia", Psychol Med, 24(2), pp.449~455 (1994)
133. Johnstone EC., "Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment", Br Med J, 2(5973), pp.724~725 (1975)
134. Spivak B., "Antinuclear autoantibodies in chronic schizophrenia", Acta Psychiatr Scand, 92(4), pp.266~269 (1995)
135. Ganguli R., "Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients", Biol Psychiatry, 32(8), pp.735~738 (1992)
136. Zorrilla EP., "Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia", Biol Psychiatry, 43(12), pp.887~896 (1998)
137. Ganguli R., "Clinical and laboratory evidence of autoimmunity in acute schizophrenia", Ann N Y Acad Sci, 496, pp.676~685 (1987)
138. Mellsop G., "Schizophrenia and autoimmune serological reactions", Arch Gen Psychiatry, 28(2), pp.194~196 (1973)
139. Sirota P., "Autoantibodies to DNA in multicase families with schizophrenia", Biol Psychiatry, 33(6), pp.450~455 (1993)
140. Chengappa KN., "Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients", Biol Psychiatry, 30(7), pp.731~735 (1991)
141. Kilidireas K., "Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia", Lancet, 340(8819), pp.569~572 (1992)
142. Kim JJ., "Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia", Schizophr Res, 52(1), pp.127~135 (2001)
143. Shinitzky M., "Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders", Ann N Y Acad Sci, 621, pp.205~217 (1991)
144. Borda T., "Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction", J Immunol, 168(7), pp.3667~3674 (2002)
145. Chengappa KN., "Antibodies to D-2 receptor in neuroleptic-naive schizophrenic patients", Biol Psychiatry, 33(97) (1993)
146. Abramson HA., "Schizophrenic sera contain antibody against brain", J Asthma Res, 4(4), pp.229~231 (1967)
147. Fessel WJ., "Autoimmunity and mental illness. A preliminary report", Arch Gen Psychiatry, 6, pp.320~323 (1962)
148. Fessel WJ., "The "antibrain" factors in psychiatric patients' sera. I. Further studies with a hemagglutination technique", Arch Gen Psychiatry, 8, pp.614~621 (1963)
149. Baron M., "Tissue-binding factor in schizophrenic sera: a clinical and genetic study", Biol Psychiatry, 12(2), pp.199~219 (1977)
150. Rimon RH., "Antibrain antibodies and interferon in the serum and the cerebrospinal fluid of patients with schizophrenia", Adv Biol Psychiatry, 12, pp.161~167 (1983)
151. Mazeh D., "Antibodies to neuroblastoma cell line proteins in patients with schizophrenia", J Neuroimmunol, 84(2), pp.218~222 (1998)
152. Jankovic BD., "Differential appearance of autoantibodies to human brain S100 protein, neuron specific enolase and myelin basic protein in psychiatric patients", Int J Neurosci, 60(1), pp.119~127 (1991)
153. Sugiura M., "Detection of anti-cerebral autoantibodies in schizophrenia and Alzheimer's disease", J Clin Lab Immunol, 28(1), pp.1~3 (1989)
154. Mukherjee S., "Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients", Schizophr Res, 12(2), pp.131~136 (1994)
155. Ganzinelli S., "Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients", Neuropharmacology, 50(3), pp.362~371 (2006)
156. Bacman S., "Circulating antibodies against neurotransmitter receptor activities in children with congenital heart block and their mothers", Faseb J, 8(14), pp.1170~1176 (1994)
157. Whitney KD, "Autoimmunity and neurological disease: antibody modulation of synaptic transmission", Annu Rev Neurosci, 22, pp.175~195 (1999)
158. Cavill D., "Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission", Arthritis Rheum, 48(12), pp.3597~3602 (2003)
159. Lang B., "Immunopathology of the Lambert-Eaton myasthenic syndrome", Springer Semin Immunopathol, 17(1), pp.3~15 (1995)
160. Takamori M., "Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome", Am J Med Sci, 319, pp.204~208 (2000)
161. Firer M., "Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia", J Clin Immunol, 14(1), pp.73~78 (1994)
162. Koliaskina GG., "Circulating immune complexes and autoantibodies in schizophrenia", Schizophr Res, 36(106) (1999)
163. Metzer WS, "Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy", South Med J, 87(2), pp.190~192 (1994)
164. DeLisi LE., "An analysis of lymphocyte subpopulations in schizophrenic patients", Biol Psychiatry, 17(9), pp.1003~1009 (1982)
165. Sirota P., "Increased anti-Sm antibodies in schizophrenic patients and their families", Prog Neuropsychopharmacol Biol Psychiatry, 17(5), pp.793~800 (1993)
166. Levy-Soussan P., "Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals", J Psychiatry Neurosci, 21(2), pp.89~95 (1996)
167. Chengappa KN., "Elevated IgG anti-histone antibodies in a subgroup of medicated schizophrenic patients", Schizophr Res, 7(1), pp.49~54 (1992)
168. Villemain F., "Anti-histone antibodies in schizophrenia and affective disorders", Psychiatry Res, 24(1), pp.53~60 (1988)
169. Legros S., "Immunoglobins, autoantibodies and other serum protein fractions in psychiatric disorders", Eur Arch Psychiatry Clin Neurosci, 235(9) (1985)
170. Singal DP., "Antibodies to thymocytes in sera of normal controls and of patients with schizophrenia", J Immunol, 114(4), pp.1425~1427 (1975)
171. Watanabe M., "Antithymic antibodies in schizophrenic sera", Biol Psychiatry, 17(6), pp.699~710 (1982)
172. Kagami M., "Cytotoxic anti-lymphocyte antibody in schizophrenics", J Neurol, 234(5), pp.359~360 (1987)
173. 오동훈, "열충격 단백질의 신경정신의학적 의의와 중요성", 생물정신의학, 14(4), pp.221~231 (2007), 대한생물정신의학회
174. Leykin I., "Elevated cellular immune response to human heat-shock protein-60 in schizophrenic patients", Eur Arch Psychiatry Clin Neurosci, 249(5), pp.238~246 (1999)
175. Wang XF., "Studies characterizing 60 kda autoantibodies in subjects with schizophrenia", Biol Psychiatry, 53(5), pp.361~375 (2003)
176. Pae CU., "Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia", Neurosci Res, 53(1), pp.8~13 (2005)
177. Reid DM., "Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier", Neuroscience, 56(3), pp.529~533 (1993)
178. Huerta PT., "Immunity and behavior: antibodies alter emotion", Proc Natl Acad Sci U S A, 103(3), pp.678~683 (2006)
179. Mayilyan KR., "Discrete MBL-MASP complexes show wide inter-individual variability in concentration: data from UK vs Armenian populations", Int J Immunopathol Pharmacol, 19(3), pp.567~580 (2006)
180. Shcherbakova I., "The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia", Immunopharmacology, 43(2), pp.273~279 (1999)
181. Kuehn BM., "Scientists probe immune system's role in brain function and neurological disease", Jama, 299(6), pp.619~620 (2008)
182. Nikkila HV., "Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation", Neuropsychobiology, 46(4), pp.169~172 (2002)
183. Rieckmann P., "Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier", J Neuroimmunol, 47(2), pp.133~140 (1993)
184. Ben-Shachar D., "Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake", J Neurochem, 62(3), pp.1112~1118 (1994)
185. Bauer K., "Blood-cerebrospinal fluid barrier in schizophrenic patients", Eur Arch Psychiatry Neurol Sci, 236(5), pp.257~259 (1987)
186. Hoekstra PJ., "Tic disorders and obsessive-compulsive disorder: is autoimmunity involved?", Int Rev Psychiatry, 17(6), pp.497~502 (2005)
187. Singer HS., "Antibrain antibodies in children with autism and their unaffected siblings", J Neuroimmunol, 178(1), pp.149~155 (2006)
188. Whitney KD., "GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins", J Neurosci, 20(19), pp.7307~7316 (2000)
189. Saunders JC., "Phenothiazine Effect on Human Antibody Synthesis", Br J Psychiatry, 110, pp.84~89 (1964)
190. Leykin I., "Short and long-term immunosuppressive effects of clozapine and haloperidol", Immunopharmacology, 37(1), pp.75~86 (1997)
191. Muller N., "Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients", Eur Psychiatry, 12, pp.249~299 (1997)
192. 김태현, "정신분열병 환자에서 항정신병약물 치료가 혈청 VEGF, sVEGFR-1 및 sVEGFR-2의 농도에 미치는 영향- 예비 연구 -", 생물정신의학, 14(4), pp.232~240 (2007), 대한생물정신의학회
193. Masserini C., "Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables", Schizophr Res, 3(4), pp.269~275 (1990)
194. Cazzullo CL., "Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study", Prog Neuropsychopharmacol Biol Psychiatry, 26(1), pp.33~39 (2002)
195. Baptista T., "Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?", Can J Psychiatry, 47(8), pp.742~749 (2002)
196. Lu LX., "Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia", Di Yi Jun Yi Da Xue Xue Bao, 24(11), pp.1251~1254 (2004)
197. Schuld A., "Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine", Schizophr Res, 43(2), pp.164~166 (2000)
198. Drzyzga L., "Cytokines in schizophrenia and the effects of antipsychotic drugs", Brain Behav Immun, 20(6), pp.532~545 (2006)
199. Szuster-Ciesielska A., "Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers", Arch Immunol Ther Exp (Warsz), 52(1), pp.59~67 (2004)
200. Ikeda K., "Chlorpromazine inhibits concanavalin A-induced liver injury independently of cytokine modulation", Immunol Lett, 55(3), pp.127~131 (1997)
201. Mengozzi M., "Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production", in mice. Immunology, 82(2), pp.207~210 (1994)
202. Tarazona R., "Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo", J Immunol, 154(2), pp.861~870 (1995)
203. Skurkovich S., "Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases", Ann N Y Acad Sci, 1051, pp.684~700 (2005)
204. Skurkovich B., "Anti-interferon-gamma antibodies in the treatment of autoimmune diseases", Curr Opin Mol Ther, 5(1), pp.52~57 (2003)
205. Levine J., "Treatment of schizophrenia with an immunosuppressant", Lancet, 344(8914), pp.59~60 (1994)
206. Riedel M., "COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date", CNS Drugs, 19(10), pp.805~819 (2005)
207. Wank R, "Schizophrenia and other mental disorders require long-term adoptive immunotherapy", Med Hypotheses, 59(2), pp.154~158 (2002)

관련 논문AI추천